This information is intended for healthcare professionals based in Ireland. If you are not a healthcare professional in Ireland, click here
HOME / ELIQUIS® (APIXABAN) DOSING INFORMATION ELIQUIS IRELAND / DOSING IN VTE-DVT / PE
Eliquis® (apixaban) dosing for adult with DVT / PE
ELIQUIS for the treatment of DVT / PE and prevention of recurrent DVT / PE
The duration of overall therapy should be individualized after careful assessment of the treatment benefit against the risk for bleeding, as per available medical guidelines, short duration of treatment (at least 3 months) should be based on transient risk factors (e.g. recent surgery, trauma, immobilisation).
Duration of overall treatment should be individualised after careful assessment of the treatment benefit against the risk for bleeding.1
No dose adjustment for adult DVT / PE patients, based on weight or those with mild-to-moderate renal impairment.1 ELIQUIS should be used with caution in adult with severe renal impairment (CrCl 15–29 ml/min) for the treatment of DVT / PE and prevention of recurrent DVT / PE.1 ELIQUIS is not recommended in patients with CrCl <15 ml/min, or in patients undergoing dialysis.1
ELIQUIS is a convenient, oral treatment for adult patients
No initial injections or bridging with LMWH required1
ELIQUIS can be taken with or without food1
Missed dose: A missed morning dose should be taken immediately when it is noticed, and it may be taken together with the evening dose. A missed evening dose can only be taken during the same evening, the patient should not take two doses the next morning. The patient should continue with the intake of the regular dose twice daily as recommended on the following day.1
Liver function testing should be performed prior to initiating ELIQUIS1
ELIQUIS (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of VTE in adult patients who have undergone elective hip or knee replacement surgery.1
Footnotes:
BD = Twice Daily CrCl = Creatinine Clearance DVT = Deep Vein LMWH = Low Molecular Weight Heparin PE = Pulmonary Embolism
References:
- ELIQUIS® (apixaban) Summary of Product Characteristics.
Date of Preparation: September 2025 | Job Description: 432-IE-2500027